EUVIMEDEUVIMED entdecken
Crossref

Can Routine Blood Tests Be Used To Predict The Prognosis of COVID-19 Patients Using Antithrombotic Drugs

Bahadir TASLİDERE, Ertan SONMEZ, Ayse KARATAS, Begüm SAKIN, Rümeyza KAZANCIOĞLU

Eurasian Journal of Critical Care · 2022

DOI: 10.55994/ejcc.1150685 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Eurasian Journal of Critical Care, 2022. Verfasst von Bahadir TASLİDERE und 4 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

COVID-19 may predispose to thromboembolism due to excessive inflammation, hypoxia, and immobilization. We investigated whether these antithrombotic drugs are useful or harmful to tackle COVID-19 and which laboratory parameters are more usable for this purpose. Materials and methods: In our study, patients diagnosed with COVID-19 while using antithrombotic drugs and COVID-19 patients who did not use antithrombotic drugs were compared. Demographic data, laboratory values, clinical results, duration of hospital stay, and mortality were noted and compared.

Results

The study was conducted on 236 patients admitted to the emergency department. The mean value of creatine, LDH, PT, NLR, troponin, and ferritin were higher in the drug-using group. Home quarantine and hospitalization rate was 68.8% (n = 33) in antiplatelet users, and 46.2% (n = 6) in the anticoagulant group.

Conclusion

The difference between the groups may have been caused by the number of chronic diseases and polypharmacy. The interaction of drugs used for the treatment of COVID-19 with antithrombotic agents is unknown. In addition, as the correlation between COVID-19 and thrombosis is not exactly known, adding antithrombotic drugs to the treatment of the disease is controversial. In our study, the biomarkers used to predict prognosis were worse in COVID-19 patients who continued antithrombotic therapy at the therapeutic dose. In the case of antithrombotic agents, the risks that may arise should always be considered. We recommend monitoring routine blood parameters, especially NLR, LDH, PT, APTT, troponin, and ferritin levels, for the prognosis monitoring of COVID-19 patients who will continue their current antithrombotic therapy

Zitieren

APA

TASLİDERE, B., SONMEZ, E., KARATAS, A., SAKIN, B., & KAZANCIOĞLU, R. (2022). Can Routine Blood Tests Be Used To Predict The Prognosis of COVID-19 Patients Using Antithrombotic Drugs. Eurasian Journal of Critical Care. https://doi.org/10.55994/ejcc.1150685

Vancouver

TASLİDERE B, SONMEZ E, KARATAS A, SAKIN B, KAZANCIOĞLU R. Can Routine Blood Tests Be Used To Predict The Prognosis of COVID-19 Patients Using Antithrombotic Drugs. Eurasian Journal of Critical Care. 2022. doi:10.55994/ejcc.1150685

BibTeX
@article{TASLDERE2022,
  author = {TASLİDERE, Bahadir and SONMEZ, Ertan and KARATAS, Ayse and SAKIN, Begüm and KAZANCIOĞLU, Rümeyza},
  title = {Can Routine Blood Tests Be Used To Predict The Prognosis of COVID-19 Patients Using Antithrombotic Drugs},
  journal = {Eurasian Journal of Critical Care},
  year = {2022},
  doi = {10.55994/ejcc.1150685}
}
Kostenlos starten →